Evidence map›Paper›PMID 29941593›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Enhancement of Ebola virus infection by seminal amyloid fibrils.

Stephen M Bart, Courtney Cohen, John M Dye, James Shorter, Paul Bates

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Innate Antiviral Defense of the Male Reproductive System.Advances in experimental medicine and biology · 2025
    Review
  4. Article
  5. Can Marburg virus be sexually transmitted?Health science reports · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Air Pollution and COVID-19: A Possible Dangerous Synergy for Male Fertility.International journal of environmental research and public health · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephen M BartDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Courtney CohenVirology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702.
John M DyeVirology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702.
James ShorterDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Paul BatesDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; pbates@pennmedicine.upenn.edu.ORCID 0000-0002-3918-5976
University of Pennsylvania · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
TRAINING IN VIROLOGYT32AI007324 · NIAID · WISTAR INSTITUTE · PI Paul Bates, Matthew D. Weitzman · 1989 to 2026
$6.8M
Generating SEVI disaggregases to prevent HIV infectionR21HD074510 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI SHORTER, JAMES · 2012 to 2013
$430k
NCI NIH HHS P30 CA016520NIAID NIH HHS T32 AI007324NICHD NIH HHS R21 HD074510
6 · The paper itself

Abstract

The 2014 western Africa Ebola virus (EBOV) epidemic was unprecedented in magnitude, infecting over 28,000 and causing over 11,000 deaths. During this outbreak, multiple instances of EBOV sexual transmission were reported, including cases where the infectious individual had recovered from EBOV disease months before transmission. Potential human host factors in EBOV sexual transmission remain unstudied. Several basic seminal amyloids, most notably semen-derived enhancer of viral infection (SEVI), enhance in vitro infection by HIV and several other viruses. To test the ability of these peptides to enhance EBOV infection, viruses bearing the EBOV glycoprotein (EboGP) were preincubated with physiological concentrations of SEVI before infection of physiologically relevant cell lines and primary cells. Preincubation with SEVI significantly increased EboGP-mediated infectivity and replication in epithelium- and monocyte-derived cell lines. This enhancement was dependent upon amyloidogenesis and positive charge, and infection results were observed with both viruses carrying EboGP and authentic EBOV as well as with semen. SEVI enhanced binding of virus to cells and markedly increased its subsequent internalization. SEVI also stimulated uptake of a fluid phase marker by macropinocytosis, a critical mechanism by which cells internalize EBOV. We report a previously unrecognized ability of SEVI and semen to significantly alter viral physical properties critical for transmissibility by increasing the stability of EboGP-bearing recombinant viruses during incubation at elevated temperature and providing resistance to desiccation. Given the potential for EBOV sexual transmission to spark new transmission chains, these findings represent an important interrogation of factors potentially important for this EBOV transmission route.

Indexed as

AmyloidEbolavirusFemaleGlycoproteinsHeLa CellsHemorrhagic Fever, EbolaHumansMaleSeminal Plasma ProteinsViral ProteinsAmyloidGlycoproteinsSeminal Plasma ProteinsViral ProteinsamyloidEbola virussemensexual transmissionvirus stabilization

Identifiers

PMID29941593
PMCPMC6048544
OpenAlexW2810726927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.